Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials

The British Journal of Dermatology
Jonathan I SilverbergBolanle Akinlade

Abstract

In the U.S.A., an Investigator's Global Assessment (IGA) score of ≤ 1 (clear or almost clear skin) has been the standard measure in regulatory outcomes for registration clinical trials in atopic dermatitis (AD), including those supporting the recent approval of dupilumab. To evaluate the treatment effect of dupilumab in patients with IGA > 1 at the end of treatment, using other validated outcome measures for AD signs, symptoms and quality of life. LIBERTY AD SOLO 1 and 2 were two 16-week, randomized, double-blind trials enrolling adult patients with moderate-to-severe AD (IGA ≥ 3) inadequately controlled with topical treatment. We performed a post hoc analysis in patients receiving dupilumab 300 mg every 2 weeks (q2w) or placebo. Outcome measures in patients with IGA > 1 included Eczema Area and Severity Index (EASI), pruritus numerical rating scale (NRS), affected body surface area (BSA), Patient-Oriented Eczema Measure (POEM) and Dermatology Life Quality Index (DLQI). The trials were registered at ClinicalTrials.gov: NCT02277743 and NCT02277769. At week 16, 278 of 449 dupilumab q2w-treated patients (median age 36·0 years) and 396 of 443 placebo-treated patients had IGA > 1. Among patients with IGA > 1 at week 16, dupilumab si...Continue Reading

References

Feb 15, 2005·Annals of the Rheumatic Diseases·S R Feldman, G G Krueger
Apr 8, 2014·Proceedings of the National Academy of Sciences of the United States of America·Andrew J MurphyGeorge D Yancopoulos
Apr 8, 2014·Proceedings of the National Academy of Sciences of the United States of America·Lynn E MacdonaldAndrew J Murphy
Dec 22, 2015·Journal of the American Academy of Dermatology·Masaki FutamuraEric L Simpson
Feb 3, 2016·JAMA : the Journal of the American Medical Association·Claus BachertE Rand Sutherland
Oct 4, 2016·The New England Journal of Medicine·Eric L SimpsonUNKNOWN SOLO 1 and SOLO 2 Investigators
Mar 10, 2017·Expert Review of Clinical Immunology·Namita A GandhiNeil M H Graham
May 22, 2018·The New England Journal of Medicine·Mario CastroAriel Teper
May 22, 2018·The New England Journal of Medicine·Klaus F RabeAriel Teper

❮ Previous
Next ❯

Citations

Mar 25, 2020·Skin Research and Technology : Official Journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)·Marco ManfrediniGiovanni Pellacani
Jul 14, 2020·The British Journal of Dermatology·A M Drucker
Sep 8, 2020·Immunotherapy·Kayla FourzaliGil Yosipovitch
Jun 11, 2020·Drugs·Megan NewsomLindsay C Strowd
May 31, 2019·Current Opinion in Allergy and Clinical Immunology·Jorien van der SchaftDeepak M W Balak
Mar 5, 2021·Pharmacology & Therapeutics·Xiaoliang YangKenji Kabashima
Feb 9, 2020·Annales de dermatologie et de vénéréologie·E Delaporte
Nov 15, 2021·Journal of the American Academy of Dermatology·Raj Chovatiya, Jonathan I Silverberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.